FidoCure® Veterinary Team Blog

Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates from our team of experts and advisors

Posts by:

Dr. Gerry Post

Rising Women in Veterinary Oncology

An introduction from Chief Medical Officer, Dr. Gerry Post

Veterinary medicine is changing. I remember one of my first days in veterinary school looking at the class pictures that were hung in the hallways. I remember seeing the first woman in one of these class photos and noting that she was still practicing.

Read More

Medical Brief:The Median Isn’t the Message

The “Median Isn’t the Message” is an essay written by Stephen J. Gould in 1991 as part of his book Bully for Brontosaurus: Reflections in Natural History. The essay has been reprinted many times for many different audiences. In 2013 it was reprinted in the American Medical Association Journal of Ethics. I believe that Stephen J. Gould’s message is as relevant today as it was when he originally wrote it. I thought this essay so important and so well written, that it was required reading for every one of my residents over the past 20 years.

Read More

Medical Brief: Sorafenib in Dogs

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs. By Laura Marconato, et al(Cancers (Basel). 2020 May 18;12(5):1272. doi: 10.3390/cancers12051272).

Read More

Unique Perspective: Cancer Biologist & Pet Cancer Parent

Dr. Elizabeth Iorns is a scientist whose research focuses on identifying mechanisms of breast cancer progression. She is a cofounder and CEO of Science Exchange, and she helped launch the Reproducibility Initiative. She was involved in the development of Olaparib, a targeted therapy directed at the BRCA1 and BRCA2 mutation, best known for its relation to breast cancer (and recently added to the FidoCure® platform).

Read More

Literature Support for Targeted Therapy

In recent academic literature, there have been more and more publications documenting that biochemical pathways in canine cancer cells are often dysregulated, and therefore, targeted therapies are likely of value.

Read More